- Home
- NCSM vs TCRX Comparison
NCSM vs TCRX Comparison
Compare NCSM & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCSM
- TCRX
- Stock Information
- Founded
- NCSM 2006
- TCRX 2018
- Country
- NCSM United States
- TCRX United States
- Employees
- NCSM N/A
- TCRX N/A
- Industry
- NCSM Oilfield Services/Equipment
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NCSM Energy
- TCRX Health Care
- Exchange
- NCSM Nasdaq
- TCRX Nasdaq
- Market Cap
- NCSM 81.3M
- TCRX 90.5M
- IPO Year
- NCSM 2017
- TCRX 2021
- Fundamental
- Price
- NCSM $29.20
- TCRX $1.46
- Analyst Decision
- NCSM
- TCRX Strong Buy
- Analyst Count
- NCSM 0
- TCRX 6
- Target Price
- NCSM N/A
- TCRX $9.50
- AVG Volume (30 Days)
- NCSM 8.1K
- TCRX 774.8K
- Earning Date
- NCSM 04-30-2025
- TCRX 05-06-2025
- Dividend Yield
- NCSM N/A
- TCRX N/A
- EPS Growth
- NCSM N/A
- TCRX N/A
- EPS
- NCSM 3.27
- TCRX N/A
- Revenue
- NCSM $168,704,000.00
- TCRX $4,421,000.00
- Revenue This Year
- NCSM $7.22
- TCRX $68.86
- Revenue Next Year
- NCSM $5.43
- TCRX $14.01
- P/E Ratio
- NCSM $8.96
- TCRX N/A
- Revenue Growth
- NCSM 18.16
- TCRX N/A
- 52 Week Low
- NCSM $15.90
- TCRX $1.02
- 52 Week High
- NCSM $38.95
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- NCSM 42.74
- TCRX 52.31
- Support Level
- NCSM $31.12
- TCRX $1.39
- Resistance Level
- NCSM $31.43
- TCRX $1.49
- Average True Range (ATR)
- NCSM 1.28
- TCRX 0.11
- MACD
- NCSM -0.35
- TCRX 0.02
- Stochastic Oscillator
- NCSM 0.00
- TCRX 82.35
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.